Medivation snaps up BioMarin's late-stage breast cancer med in $410M-plus deal

Lots of companies are working to bulk up in the cancer field--but not BioMarin ($BMRN). Buckling down on rare diseases, the company is out-licensing its Phase III PARP inhibitor to Medivation ($MDVN) for $410 million up front, with another $160 million in milestones. The prospect--talazoparib--entered Phase III back in 2013 for advanced breast cancer among patients with BRCA 1 or BRCA 2 mutations, and Medivation is hoping to add it to a marketed portfolio that already includes the successful prostate cancer pill Xtandi. More

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.